3,4-DAA |
| Catalog No.GC12624 |
synthetic derivative of the tryptophan metabolite anthranilic acid
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2117759-07-4
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
N-(3,4,-Dimethoxycinnamoyl) anthranilic acid (3,4-DAA) is a synthetic derivative of the tryptophan metabolite anthranilic acid [1].
Degradation of the essential amino acid Trp by indoleamine 2,3-dioxygenase (IDO) plays an important role in immunity. IDO has been implicated in immune modulation through limiting T cell function and engage mechanisms of immune tolerance. Activation of IDO has been observed during tumor development, helping malignant cells escape eradication by the immune system [2].
3,4-DAA suppressed antigen-specific proliferation of MBP Ac1-11 TCR transgenic CD4+ T cells by arrested the cells in G1/S-phase. 3,4-DAA (200 μM) reduced the release of IL-2, IFN-γ, and TNF-α and 3,4-DAA (30 μM)increased the level of IL-4 and IL-10 in splenocytes from MBP Ac1-11 TCR transgenic T cells after antigen stimulation [1]. 3,4-DAA dose-dependently decreased IFNγ–induced cell surface expression of MHC class II and costimulatory molecules and suppressed the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells and phosphorylation of STAT1α induced by IFNγ. In Mice with experimental autoimmune encephalomyelitis, oral administration of 3,4-DAA (300 mg/kg per day) exhibited fewer and milder relapses and less severe disease compared to control animals [1]. In allograft immunorejection model, administration of 3,4-DAA reduced histological severity of allograft immunorejection, decreased serum levels of TNF-α and IFN-γ, and raised serum levels of IL-10 [3].
References:
[1] Platten M, Ho P P, Youssef S, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite[J]. Science, 2005, 310(5749): 850-855.
[2] Hirata F, Ohnishi T, Hayaishi O. Indoleamine 2, 3-Dioxygenase[J]. J. Biol. Chem, 1977, 252: 4637.
[3] Sun Q F, Ding J G, Sheng J F, et al. Novel action of 3, 4‐DAA ameliorating acute liver allograft injury[J]. Cell biochemistry and function, 2011, 29(8): 673-678.
| Cas No. | 2117759-07-4 | SDF | |
| Chemical Name | 2-[3-(3,4-dimethoxy-phenyl)-acryloylamino]-3-hydroxy-benzoic acid | ||
| Canonical SMILES | COC1=C(OC)C=C(/C=C/C(NC2=C(O)C=CC=C2C(O)=O)=O)C=C1 | ||
| Formula | C18H17NO6 | M.Wt | 343.3 |
| Solubility | DMF: 30 mg/ml,DMF:PBS (pH 7.2) (1:1): .5 mg/ml,DMSO: 20 mg/ml,Ethanol: 1 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9129 mL | 14.5645 mL | 29.129 mL |
| 5 mM | 0.5826 mL | 2.9129 mL | 5.8258 mL |
| 10 mM | 0.2913 mL | 1.4565 mL | 2.9129 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *